Genvac-B Indications/Uses

GENVAC-B is indicated for active immunisation against Hepatitis B infection in subjects considered at risk of exposure to HBV-positive material.
Immunisation against Hepatitis B is expected in the long term to reduce not only the incidence of this disease, but also its chronic complications such as chronic active Hepatitis B and Hepatitis B associated cirrhosis and primary hepatocellular carcinoma.
In areas of low prevalence of Hepatitis B, immunisation with Hepatitis B vaccine is recommended for neonates/infants and adolescents as well as for subjects who are, or will be, at increased risk of infection such as: Health Care Personnel.
Patients receiving frequent blood products.
Personnel and residents of institution.
Persons at increased risk due to their sexual behaviour.
Illicit users of addictive injectable drugs.
Travellers to areas with a high endemicity of HBV.
Infants born of mothers who are HBV carries.
Persons originating from areas with a high endemicity of HBV.
Others: Police personnel, fire brigade personnel, armed forces personnel and anybody who through their work or personal lifestyle may be exposed to HBV.
Household contacts of any of the previously mentioned groups and of patients with acute or chronic HBV infection.
In areas of intermediate or high prevalence of Hepatitis B, with most of the population at risk of acquiring the disease, immunisation should be offered to all neonates and young children. Immunisation should also be considered for adolescents and young adults.
The vaccine can be safely and effectively given simultaneously but at different injection site with DTP, DT, TT, BCG, Measles, Polio vaccine (OPV and IPV) and yellow fever vaccine. It should not be mixed in the vial or syringe with any other vaccine unless it is manufactured as a combined product (e.g. DTP-Hep B).